Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia

British Journal of Haematology

Volumn 175, Issue 2, 2016, Pages 226-236

  Bhatnagar, Bhavana ^a   Eisfeld, Ann Kathrin ^a   Nicolet, Deedra ^a,b   Mrózek, Krzysztof ^a   Blachly, James S ^a   Orwick, Shelley ^a   Lucas, David M ^a   Kohlschmidt, Jessica ^a,b   Blum, William ^a   Kolitz, Jonathan E ^c   Stone, Richard M ^d   Bloomfield, Clara D ^a   Byrd, John C ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

acute myeloid leukaemia; DNA (cytosine 5) methyltransferase 3 alpha; mutation clearance; prognosis; survival

Indexed keywords

CYTARABINE; DAUNORUBICIN; DNA METHYLTRANSFERASE 3A; JANUS KINASE 2; PROTEIN P53; CODON; DNA (CYTOSINE 5) METHYLTRANSFERASE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASXL1 GENE; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNMT3A GENE; FEMALE; GENE; GENE FREQUENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; JAK2 GENE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PRIORITY JOURNAL; SOMATIC MUTATION; SURVIVAL TIME; TET2 GENE; TP53 GENE; AMINO ACID SUBSTITUTION; BONE MARROW; CODON; DNA MUTATIONAL ANALYSIS; GENETICS; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; AMINO ACID SUBSTITUTION; BONE MARROW; CODON; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; PROGNOSIS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84994473906     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14254     Document Type: Article

References (44)

1. Attar, E.C., Johnson, J.L., Amrein, P.C., Lozanski, G., Wadleigh, M., DeAngelo, D.J., Kolitz, J.E., Powell, B.L., Voorhees, P., Wang, E.S., Blum, W., Stone, R.M., Marcucci, G., Bloomfield, C.D., Moser, B. & Larson, R.A. (2013) Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. Journal of Clinical Oncology, 31, 923–929.
2. Baer, M.R., George, S.L., Dodge, R.K., O'Loughlin, K.L., Minderman, H., Caligiuri, M.A., Anastasi, J., Powell, B.L., Kolitz, J.E., Schiffer, C.A., Bloomfield, C.D. & Larson, R.A. (2002) Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood, 100, 1224–1232.
3. Blum, W., Sanford, B., Klisovic, R.B., DeAngelo, D.A., Uy, G., Powell, B.L., Stock, W., Baer, M.R., Kolitz, J.E., Wetzler, M., Hoke, E., Bloomfield, C.D., Geyer, S., Marcucci, G., Stone, R.M. & Larson, R.A. (2012) Maintenance therapy with decitabine in younger adults with acute myeloid leukemia (AML) in first remission: a phase II Cancer and Leukemia Group B study (CALGB 10503, Alliance) [abstract]. Blood, 120. Abstract 44.
4. Byrd, J.C., Mrόzek, K., Dodge, R.K., Carroll, A.J., Edwards, C.G., Arthur, D.C., Pettenati, M.J., Patil, S.R., Rao, K.W., Watson, M.S., Koduru, P.R., Moore, J.O., Stone, R.M., Mayer, R.J., Feldman, E.J., Davey, F.R., Schiffer, C.A., Larson, R.A. & Bloomfield, C.D. (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 100, 4325–4336.
5. Challen, G.A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J.S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., Liang, S., Lu, Y., Darlington, G.J., Meissner, A., Issa, J.P., Godley, L.A., Li, W. & Goodell, M.A. (2012) Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genetics, 44, 23–31.
6. Cibulskis, K., Lawrence, M.S., Carter, S.L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E.S. & Getz, G. (2013) Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature Biotechnology, 31, 213–219.
7. Corces-Zimmerman, M.R., Hong, W.J., Weissman, I.L., Medeiros, B.C. & Majeti, R. (2014) Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proceedings of the National Academy of Sciences of the United States of America, 111, 2548–2553.
8. Debarri, H., Lebon, D., Roumier, C., Cheok, M., Marceau-Renaut, A., Nibourel, O., Geffroy, S., Helevaut, N., Rousselot, P., Gruson, B., Gardin, C., Chretien, M.L., Sebda, S., Figeac, M., Berthon, C., Quesnel, B., Boissel, N., Castaigne, S., Dombret, H., Renneville, A. & Preudhomme, C. (2015) IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget, 6, 42345–42353.
9. DePristo, M.A., Banks, E., Poplin, R., Garimella, K.V., Maguire, J.R., Hartl, C., Philippakis, A.A., del Angel, G., Rivas, M.A., Hanna, M., McKenna, A., Fennell, T.J., Kernytsky, A.M., Sivachenko, A.Y., Cibulskis, K., Gabriel, S.B., Altshuler, D. & Daly, M.J. (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature Genetics, 43, 491–498.
10. Döhner, H., Estey, E.H., Amadori, S., Appelbaum, F.R., Büchner, T., Burnett, A.K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R.A., Lo-Coco, F., Naoe, T., Niederwieser, D., Ossenkoppele, G.J., Sanz, M.A., Sierra, J., Tallman, M.S., Löwenberg, B. & Bloomfield, C.D. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 115, 453–474.
11. Gaidzik, V.I., Schlenk, R.F., Paschka, P., Stölzle, A., Späth, D., Kuendgen, A., von Lilienfeld-Toal, M., Brugger, W., Derigs, H.G., Kremers, S., Greil, R., Raghavachar, A., Ringhoffer, M., Salih, H.R., Wattad, M., Kirchen, H.G., Runde, V., Heil, G., Petzer, A.L., Girschikofsky, M., Heuser, M., Kayser, S., Goehring, G., Teleanu, M.V., Schlegelberger, B., Ganser, A., Krauter, J., Bullinger, L., Döhner, H. & Döhner, K. (2013) Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood, 121, 4769–4777.
12. Gale, R.E., Lamb, K., Allen, C., El-Sharkawi, D., Stowe, C., Jenkinson, S., Tinsley, S., Dickson, G., Burnett, A.K., Hills, R.K. & Linch, D.C. (2015) Simpson's paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia. Journal of Clinical Oncology, 33, 2072–2083.
13. Genovese, G., Kähler, A.K., Handsaker, R.E., Lindberg, J., Rose, S.A., Bakhoum, S.F., Chambert, K., Mick, E., Neale, B.M., Fromer, M., Purcell, S.M., Svantesson, O., Landén, M., Höglund, M., Lehmann, S., Gabriel, S.B., Moran, J.L., Lander, E.S., Sullivan, P.F., Sklar, P., Grönberg, H., Hultman, C.M. & McCarroll, S.A. (2014) Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. New England Journal of Medicine, 371, 2477–2487.
14. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. & Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood, 92, 2322–2333.
15. Hou, H.A., Kuo, Y.Y., Liu, C.Y., Chou, W.C., Lee, M.C., Chen, C.Y., Lin, L.I., Tseng, M.H., Huang, C.F., Chiang, Y.C., Lee, F.Y., Liu, M.C., Liu, C.W., Tang, J.L., Yao, M., Huang, S.Y., Ko, B.S., Hsu, S.C., Wu, S.J., Tsay, W., Chen, Y.C. & Tien, H.F. (2012) DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood, 119, 559–568.
16. Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P.V., Mar, B.G., Lindsley, R.C., Mermel, C.H., Burtt, N., Chavez, A., Higgins, J.M., Moltchanov, V., Kuo, F.C., Kluk, M.J., Henderson, B., Kinnunen, L., Koistinen, H.A., Ladenvall, C., Getz, G., Correa, A., Banahan, B.F., Gabriel, S., Kathiresan, S., Stringham, H.M., McCarthy, M.I., Boehnke, M., Tuomilehto, J., Haiman, C., Groop, L., Atzmon, G., Wilson, J.G., Neuberg, D., Altshuler, D. & Ebert, B.L. (2014) Age-related clonal hematopoiesis associated with adverse outcomes. New England Journal of Medicine, 371, 2488–2498.
17. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of American Statistical Association, 53, 457–481.
18. Kim, S.J., Zhao, H., Hardikar, S., Singh, A.K., Goodell, M.A. & Chen, T. (2013) A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood, 122, 4086–4089.
19. Klco, J.M., Miller, C.A., Griffith, M., Petti, A., Spencer, D.H., Ketkar-Kulkarni, S., Wartman, L.D., Christopher, M., Lamprecht, T.L., Helton, N.M., Duncavage, E.J., Payton, J.E., Baty, J., Heath, S.E., Griffith, O.L., Shen, D., Hundal, J., Chang, G.S., Fulton, R., O'Laughlin, M., Fronick, C., Magrini, V., Demeter, R.T., Larson, D.E., Kulkarni, S., Ozenberger, B.A., Welch, J.S., Walter, M.J., Graubert, T.A., Westervelt, P., Radich, J.P., Link, D.C., Mardis, E.R., DiPersio, J.F., Wilson, R.K. & Ley, T.J. (2015) Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA, 314, 811–822.
20. Kolitz, J.E., George, S.L., Dodge, R.K., Hurd, D.D., Powell, B.L., Allen, S.L., Velez-Garcia, E., Moore, J.O., Shea, T.C., Hoke, E., Caligiuri, M.A., Vardiman, J.W., Bloomfield, C.D. & Larson, R.A. (2004) Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. Journal of Clinical Oncology, 22, 4290–4301.
21. Kolitz, J.E., George, S.L., Marcucci, G., Vij, R., Powell, B.L., Allen, S.L., DeAngelo, D.J., Shea, T.C., Stock, W., Baer, M.R., Hars, V., Maharry, K., Hoke, E., Vardiman, J.W., Bloomfield, C.D. & Larson, R.A., for the Cancer & Leukemia Group B. (2010) P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood, 116, 1413–1421.
22. Kroll, K.W., Eisfeld, A.K., Lozanski, G., Bloomfield, C.D., Byrd, J.C. & Blachly, J.S. (2016) MuCor: mutation aggregation and correlation. Bioinformatics, 32, 1557–1558.
23. Krönke, J., Bullinger, L., Teleanu, V., Tschürtz, F., Gaidzik, V.I., Kühn, M.W., Rücker, F.G., Holzmann, K., Paschka, P., Kapp-Schwörer, S., Späth, D., Kindler, T., Schittenhelm, M., Krauter, J., Ganser, A., Göhring, G., Schlegelberger, B., Schlenk, R.F., Döhner, H. & Döhner, K. (2013) Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood, 122, 100–108.
24. Ley, T.J., Ding, L., Walter, M.J., McLellan, M.D., Lamprecht, T., Larson, D.E., Kandoth, C., Payton, J.E., Baty, J., Welch, J., Harris, C.C., Lichti, C.F., Townsend, R.R., Fulton, R.S., Dooling, D.J., Koboldt, D.C., Schmidt, H., Zhang, Q., Osborne, J.R., Lin, L., O'Laughlin, M., McMichael, J.F., Delehaunty, K.D., McGrath, S.D., Fulton, L.A., Magrini, V.J., Vickery, T.L., Hundal, J., Cook, L.L., Conyers, J.J., Swift, G.W., Reed, J.P., Alldredge, P.A., Wylie, T., Walker, J., Kalicki, J., Watson, M.A., Heath, S., Shannon, W.D., Varghese, N., Nagarajan, R., Westervelt, P., Tomasson, M.H., Link, D.C., Graubert, T.A., DiPersio, J.F., Mardis, E.R. & Wilson, R.K. (2010) DNMT3A mutations in acute myeloid leukemia. New England Journal of Medicine, 363, 2424–2433.
25. Marcucci, G., Moser, B., Blum, W., Stock, W., Wetzler, M., Kolitz, J.E., Thakuri, M., Carter, T., Stuart, R.K. & Larson, R.A. (2007) A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apopatientotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old [abstract]. Journal of Clinical Oncology, 25(suppl), 360s. Abstract 7012.
26. Marcucci, G., Maharry, K., Radmacher, M.D., Mrόzek, K., Vukosavljevic, T., Paschka, P., Whitman, S.P., Langer, C., Baldus, C.D., Liu, C.G., Ruppert, A.S., Powell, B.L., Carroll, A.J., Caligiuri, M.A., Kolitz, J.E., Larson, R.A. & Bloomfield, C.D. (2008) Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 26, 5078–5087.
27. Marcucci, G., Metzeler, K.H., Schwind, S., Becker, H., Maharry, K., Mrόzek, K., Radmacher, M.D., Kohlschmidt, J., Nicolet, D., Whitman, S.P., Wu, Y.Z., Powell, B.L., Carter, T.H., Kolitz, J.E., Wetzler, M., Carroll, A.J., Baer, M.R., Moore, J.O., Caligiuri, M.A., Larson, R.A. & Bloomfield, C.D. (2012) Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. Journal of Clinical Oncology, 30, 742–750.
28. Mayle, A., Yang, L., Rodriguez, B., Zhou, T., Chang, E., Curry, C.V., Challen, G.A., Li, W., Wheeler, D., Rebel, V.I. & Goodell, M.A. (2015) Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood, 125, 629–638.
29. Moore, J.O., George, S.L., Dodge, R.K., Amrein, P.C., Powell, B.L., Kolitz, J.E., Baer, M.R., Davey, F.R., Bloomfield, C.D., Larson, R.A. & Schiffer, C.A. (2005) Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood, 105, 3420–3427.
30. Mrόzek, K., Heerema, N.A. & Bloomfield, C.D. (2004) Cytogenetics in acute leukemia. Blood Reviews, 18, 115–136.
31. Mrόzek, K., Carroll, A.J., Maharry, K., Rao, K.W., Patil, S.R., Pettenati, M.J., Watson, M.S., Arthur, D.C., Tantravahi, R., Heerema, N.A., Koduru, P.R.K., Block, A.W., Qumsiyeh, M.B., Edwards, C.G., Sterling, L.J., Holland, K.B. & Bloomfield, C.D. (2008) Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. International Journal of Oncology, 33, 239–244.
32. Mrόzek, K., Marcucci, G., Nicolet, D., Maharry, K.S., Becker, H., Whitman, S.P., Metzeler, K.H., Schwind, S., Wu, Y.Z., Kohlschmidt, J., Pettenati, M.J., Heerema, N.A., Block, A.W., Patil, S.R., Baer, M.R., Kolitz, J.E., Moore, J.O., Carroll, A.J., Stone, R.M., Larson, R.A. & Bloomfield, C.D. (2012) Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. Journal of Clinical Oncology, 30, 4515–4523.
33. Pløen, G.G., Nederby, L., Guldberg, P., Hansen, M., Ebbesen, L.H., Jensen, U.B., Hokland, P. & Aggerholm, A. (2014) Persistence of DNMT3A mutations at long-term remission in adult patients with AML. British Journal of Haematology, 167, 478–486.
34. Renneville, A., Boissel, N., Nibourel, O., Berthon, C., Helevaut, N., Gardin, C., Cayuela, J.M., Hayette, S., Reman, O., Contentin, N., Bordessoule, D., Pautas, C., Botton, S., Revel, T., Terre, C., Fenaux, P., Thomas, X., Castaigne, S., Dombret, H. & Preudhomme, C. (2012) Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia, 26, 1247–1254.
35. Ribeiro, A.F.T., Pratcorona, M., Erpelinck-Verschueren, C., Rockova, V., Sanders, M., Abbas, S., Figueroa, M.E., Zeilemaker, A., Melnick, A., Löwenberg, B., Valk, P.J.M. & Delwel, R. (2012) Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood, 119, 5824–5831.
36. Robinson, J.T., Thorvaldsdottir, H., Winckler, W., Guttman, M., Lander, E.S., Getz, G. & Mesirov, J.P. (2011) Integrative genomics viewer. Nature Biotechnology, 29, 24–26.
37. Russler-Germain, D.A., Spencer, D.H., Young, M.A., Lamprecht, T.L., Miller, C.A., Fulton, R., Meyer, M.R., Erdmann-Gilmore, P., Townsend, R.R., Wilson, R.K. & Ley, T.J. (2014) The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell, 25, 442–454.
38. Shlush, L.I., Zandi, S., Mitchell, A., Chen, W.C., Brandwein, J.M., Gupta, V., Kennedy, J.A., Schimmer, A.D., Schuh, A.C., Yee, K.W., McLeod, J.L., Doedens, M., Medeiros, J.J.F., Marke, R., Kim, H.J., Lee, K., McPherson, J.D. & Hudson, T.J.; HALT Pan-Leukemia Gene Panel Consortium, Brown, A.M.K., Yousif, F., Trinh, Q.M., Stein, L.D., Minden, M.D., Wang, J.C.Y. & Dick, J.E. (2014) Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature, 506, 328–333.
39. Steensma, D.P., Bejar, R., Jaiswal, S., Lindsley, R.C., Sekeres, M.A., Hasserjian, R.P. & Ebert, B.L. (2015) Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood, 126, 9–16.
40. Stone, R.M., Fischer, T., Paquette, R., Schiller, G., Schiffer, C.A., Ehninger, G., Cortes, J., Kantarjian, H.M., DeAngelo, D.J., Huntsman-Labed, A., Dutreix, C., del Corral, A. & Giles, F. (2012) Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia, 26, 2061–2068.
41. Thol, F., Damm, F., Lüdeking, A., Winschel, C., Wagner, K., Morgan, M., Yun, H., Göhring, G., Schlegelberger, B., Hoelzer, D., Lübbert, M., Kanz, L., Fiedler, W., Kirchner, H., Heil, G., Krauter, J., Ganser, A. & Heuser, M. (2011) Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. Journal of Clinical Oncology, 29, 2889–2896.
42. Vittinghoff, E., Glidden, D.V., Shiboski, S.C. & McCulloch, C.E. (2005) Regression Methods in Biostatistics: Linear, Logistic, Survival and Repeated Measures Models. Springer, New York, NY.
43. Westfall, P.H., Tobias, R.D., Rom, D., Wolfinger, R.D. & Hochberg, Y. (1999) Multiple Comparisons and Multiple Tests Using the SAS System. SAS Institute, Cary, NC.
44. Xie, M., Lu, C., Wang, J., McLellan, M.D., Johnson, K.J., Wendl, M.C., McMichael, J.F., Schmidt, H.K., Yellapantula, V., Miller, C.A., Ozenberger, B.A., Welch, J.S., Link, D.C., Walter, M.J., Mardis, E.R., Dipersio, J.F., Chen, F., Wilson, R.K., Ley, T.J. & Ding, L. (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nature Medicine, 20, 1472–1478.